[go: up one dir, main page]

BR112022024374A2 - Composições farmacêuticas de pralsetinibe - Google Patents

Composições farmacêuticas de pralsetinibe

Info

Publication number
BR112022024374A2
BR112022024374A2 BR112022024374A BR112022024374A BR112022024374A2 BR 112022024374 A2 BR112022024374 A2 BR 112022024374A2 BR 112022024374 A BR112022024374 A BR 112022024374A BR 112022024374 A BR112022024374 A BR 112022024374A BR 112022024374 A2 BR112022024374 A2 BR 112022024374A2
Authority
BR
Brazil
Prior art keywords
pralsetinib
pharmaceutically acceptable
compositions
pharmaceutical compositions
present disclosure
Prior art date
Application number
BR112022024374A
Other languages
English (en)
Inventor
Waetzig Joshua
D Wilkie Gordon
L Mazaik Debra
M Varga Csanad
Rogal Lia
Maceachern Lauren
Jean Miller Kimberly
Rigby-Singleton Shellie
A Barker Ian
j harris Robert
J Spenceley Aimee
Gordhan Dipak
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of BR112022024374A2 publication Critical patent/BR112022024374A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS DE PRALSETINIBE. A presente divulgação refere-se à composição farmacêutica que compreende 1) uma dispersão sólida amorfa compreendendo pralsetinibe, ou um sal farmaceuticamente aceitável do mesmo; e um polímero hidrofílico farmaceuticamente aceitável; e 2) um par efervescente; e formas cristalinas de pralsetinibe e sal cloridrato de pralsetinibe, que são úteis como inibidores seletivos do RET. A presente divulgação também fornece composições farmaceuticamente aceitáveis que compreendem as formas cristalinas e métodos de uso das referidas composições no tratamento de diversos distúrbios.
BR112022024374A 2020-05-29 2021-05-28 Composições farmacêuticas de pralsetinibe BR112022024374A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032030P 2020-05-29 2020-05-29
PCT/US2021/034811 WO2021243186A1 (en) 2020-05-29 2021-05-28 Pralsetinib pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR112022024374A2 true BR112022024374A2 (pt) 2023-05-02

Family

ID=76641805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024374A BR112022024374A2 (pt) 2020-05-29 2021-05-28 Composições farmacêuticas de pralsetinibe

Country Status (15)

Country Link
US (1) US20230203009A1 (pt)
EP (1) EP4157230A1 (pt)
JP (1) JP2023501757A (pt)
KR (1) KR20230017229A (pt)
CN (1) CN116133646A (pt)
AU (1) AU2021281283A1 (pt)
BR (1) BR112022024374A2 (pt)
CA (1) CA3184648A1 (pt)
CL (1) CL2022003353A1 (pt)
CR (1) CR20220666A (pt)
IL (1) IL298525A (pt)
MX (1) MX2022015022A (pt)
PE (1) PE20231425A1 (pt)
TW (1) TW202210079A (pt)
WO (1) WO2021243186A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3773589T (lt) 2018-04-03 2024-02-12 Blueprint Medicines Corporation Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui
PE20221582A1 (es) 2019-12-19 2022-10-06 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de receptor de androgenos
IT202300006819A1 (it) * 2023-04-06 2024-10-06 Olon Spa Processo per preparare pralsetinib in forma amorfa, e relativi intermedi in forma cristallina.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
WO2013170159A1 (en) * 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
SG11201803653QA (en) 2015-11-02 2018-05-30 Blueprint Medicines Corp Inhibitors of ret
EP3624802A1 (en) * 2017-05-15 2020-03-25 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
WO2020033838A2 (en) * 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
KR20220123057A (ko) * 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법

Also Published As

Publication number Publication date
PE20231425A1 (es) 2023-09-13
MX2022015022A (es) 2023-03-08
US20230203009A1 (en) 2023-06-29
CL2022003353A1 (es) 2023-07-14
CR20220666A (es) 2023-05-05
EP4157230A1 (en) 2023-04-05
KR20230017229A (ko) 2023-02-03
CA3184648A1 (en) 2021-12-02
WO2021243186A1 (en) 2021-12-02
CN116133646A (zh) 2023-05-16
JP2023501757A (ja) 2023-01-18
TW202210079A (zh) 2022-03-16
IL298525A (en) 2023-01-01
AU2021281283A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
EP4424372A3 (en) Compounds and methods for treatment of viral infections
BR112022024374A2 (pt) Composições farmacêuticas de pralsetinibe
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
BRPI0709581A8 (pt) compostos de bicicloeteroarila como moduladores de px27 e seu uso
UY30442A1 (es) Composiciones farmaccuticas de ropinirol, mctodos de uso, proceso de preparacinn y aplicaciones.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
NO331211B1 (no) ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿
EP4537828A3 (en) Phospholipid compounds and uses thereof
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BR112023018472A2 (pt) Composições de psilocibina, métodos de produção e métodos de uso das mesmas
BR112012008650A2 (pt) n-((1r,2s,5r)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]tria-zin-4-ilamino)-2-oxopirrolidin-1-il)cicloexil)acetamida, um modulador dual de atividade de receptor de quimiocina, formas cristalinas e processos
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
WO2007044357A3 (en) Formulations of aica riboside
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR112022018657A2 (pt) Anticorpos, ácido nucleico, célula hospedeira, imunoconjugado, formulação farmacêutica, usos de um anticorpo, métodos de produção de um anticorpo e de tratamento de um indivíduo, métodos para inibir a sinalização de smad e para diagnosticar um indivíduo como tendo ssc e kit
ATE548043T1 (de) Polymorphe von 3-o-(3',3'- dimethylsuccinyl)betulinsäure-di-n-methyl-d- glucamin
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CO2022006066A2 (es) Agente terapéutico y agente profiláctico para trastornos gastrointestinales funcionales y xerostomía

Legal Events

Date Code Title Description
B10A Cessation: cessation confirmed